EG24223A - Stabilized formulations of 6-hydroxy-3-(4-[2-(piperidin-1-yl)ethoxy]phenoxy)-2-(4-methoxyphenyl)benzo[b] thiopehene and salts thereof - Google Patents

Stabilized formulations of 6-hydroxy-3-(4-[2-(piperidin-1-yl)ethoxy]phenoxy)-2-(4-methoxyphenyl)benzo[b] thiopehene and salts thereof

Info

Publication number
EG24223A
EG24223A EG20010461A EG20010461A EG24223A EG 24223 A EG24223 A EG 24223A EG 20010461 A EG20010461 A EG 20010461A EG 20010461 A EG20010461 A EG 20010461A EG 24223 A EG24223 A EG 24223A
Authority
EG
Egypt
Prior art keywords
piperidin
benzo
methoxyphenyl
phenoxy
ethoxy
Prior art date
Application number
EG20010461A
Other languages
English (en)
Inventor
Bashore N Fadia
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Application granted granted Critical
Publication of EG24223A publication Critical patent/EG24223A/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4535—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom, e.g. pizotifen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Neurosurgery (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Obesity (AREA)
  • Hospice & Palliative Care (AREA)
  • Vascular Medicine (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Toxicology (AREA)
  • Psychiatry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
EG20010461A 2000-05-08 2001-05-05 Stabilized formulations of 6-hydroxy-3-(4-[2-(piperidin-1-yl)ethoxy]phenoxy)-2-(4-methoxyphenyl)benzo[b] thiopehene and salts thereof EG24223A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US20323500P 2000-05-08 2000-05-08

Publications (1)

Publication Number Publication Date
EG24223A true EG24223A (en) 2008-11-10

Family

ID=22753086

Family Applications (1)

Application Number Title Priority Date Filing Date
EG20010461A EG24223A (en) 2000-05-08 2001-05-05 Stabilized formulations of 6-hydroxy-3-(4-[2-(piperidin-1-yl)ethoxy]phenoxy)-2-(4-methoxyphenyl)benzo[b] thiopehene and salts thereof

Country Status (31)

Country Link
EP (1) EP1357903B1 (es)
JP (1) JP2003535827A (es)
KR (1) KR100806992B1 (es)
CN (1) CN1283250C (es)
AR (1) AR028401A1 (es)
AT (1) ATE348605T1 (es)
AU (2) AU5531001A (es)
BR (1) BR0110620A (es)
CA (2) CA2408563A1 (es)
CZ (1) CZ20023651A3 (es)
DE (1) DE60125416T2 (es)
DZ (1) DZ3376A1 (es)
EA (1) EA004871B1 (es)
EC (1) ECSP014066A (es)
EG (1) EG24223A (es)
ES (1) ES2276784T3 (es)
HK (1) HK1061349A1 (es)
HR (1) HRP20020883A2 (es)
HU (1) HUP0302190A3 (es)
IL (2) IL152699A0 (es)
MX (1) MXPA02010923A (es)
NO (1) NO20025219D0 (es)
NZ (1) NZ521393A (es)
PE (1) PE20011255A1 (es)
PL (1) PL365472A1 (es)
SK (1) SK286346B6 (es)
SV (1) SV2002000435A (es)
TW (1) TWI225787B (es)
UA (1) UA77941C2 (es)
WO (1) WO2001085147A2 (es)
ZA (1) ZA200207651B (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6610706B1 (en) 1999-07-29 2003-08-26 Eli Lilly And Company Crystalline form of 6-hydroxy-3-(4-[2-(piperidin-1-yl)ethoxy]phenoxy)-2-(4-methoxyphenyl)benzo[b]thiophene hydrochloride
US6653479B1 (en) 1999-07-29 2003-11-25 Eli Lilly And Company Crystalline form of 6-hydroxy-3-(4-[2-(piperidin-1-yl)ethoxy]phenoxy)-2-(4-methoxyphenyl)benzo[b] thiophene hydrochloride
JP4593469B2 (ja) * 2003-09-22 2010-12-08 杏林製薬株式会社 変色改善された５−アミノサリチル酸固形製剤およびその保存方法
WO2016024369A1 (ja) * 2014-08-13 2016-02-18 テバ製薬株式会社 がん治療用医薬組成物

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2163587T3 (es) * 1995-02-28 2002-02-01 Lilly Co Eli Compuestos de benzotiofeno, productos intermedios, composiciones y procedimientos.
ZA982877B (en) * 1997-04-09 1999-10-04 Lilly Co Eli Treatment of central nervous system disorders with selective estrogen receptor modulators.
WO2001009116A2 (en) * 1999-07-29 2001-02-08 Eli Lilly And Company A NOVEL CRYSTALLINE FORM OF 6-HYDROXY-3- (4-[2-(PIPERIDIN-1-YL) ETHOXY]PHENOXY)- 2-(4-METHOXYPHENYL)BENZO[b]THIOPHENE HYDROCHLORIDE
AU780211B2 (en) * 1999-07-29 2005-03-10 Eli Lilly And Company Crystalline form of 6-hydroxy-3-(4-(2-(piperidin-1-yl) ethoxy)phenoxy)-2-(4-methoxyphenyl)benzo[b]thiophene hydrochloride
AU6335500A (en) * 1999-07-29 2001-02-19 Eli Lilly And Company A novel crystalline form of 6-hydroxy-3-(4-[2-(piperidin-1-yl)ethoxy]phenoxy)-2-(4-metho yphenyl)benzo[b]thiophene hydrochloride

Also Published As

Publication number Publication date
SK286346B6 (en) 2008-07-07
EA004871B1 (ru) 2004-08-26
SV2002000435A (es) 2002-10-24
EA200201186A1 (ru) 2003-08-28
DZ3376A1 (fr) 2001-11-15
AU2001255310B8 (en) 2005-03-10
HUP0302190A3 (en) 2009-03-30
IL152699A0 (en) 2003-06-24
CZ20023651A3 (cs) 2003-02-12
ES2276784T3 (es) 2007-07-01
NO20025219L (no) 2002-10-31
EP1357903B1 (en) 2006-12-20
KR20030009477A (ko) 2003-01-29
PE20011255A1 (es) 2001-12-11
BR0110620A (pt) 2003-04-01
MXPA02010923A (es) 2003-03-27
CN1283250C (zh) 2006-11-08
AU5531001A (en) 2001-11-20
TWI225787B (en) 2005-01-01
ECSP014066A (es) 2002-02-25
ZA200207651B (en) 2003-12-23
NZ521393A (en) 2004-08-27
UA77941C2 (en) 2007-02-15
CA2691739A1 (en) 2001-11-15
HRP20020883A2 (en) 2005-02-28
ATE348605T1 (de) 2007-01-15
EP1357903A2 (en) 2003-11-05
NO20025219D0 (no) 2002-10-31
AU2001255310B2 (en) 2005-03-03
CA2408563A1 (en) 2001-11-15
DE60125416T2 (de) 2007-09-27
KR100806992B1 (ko) 2008-02-25
AR028401A1 (es) 2003-05-07
SK15652002A3 (sk) 2003-04-01
HUP0302190A2 (hu) 2003-10-28
JP2003535827A (ja) 2003-12-02
WO2001085147A2 (en) 2001-11-15
HK1061349A1 (en) 2004-09-17
PL365472A1 (en) 2005-01-10
DE60125416D1 (de) 2007-02-01
AU2001255310C1 (en) 2006-03-09
IL152699A (en) 2009-09-01
CN1545413A (zh) 2004-11-10
WO2001085147A3 (en) 2003-08-28

Similar Documents

Publication Publication Date Title
CY1107512T1 (el) Νεες υποκατεστημενες με βενζιμιδαζολιο μορφες δοσολογιας και μεθοδος για τη χρηση τους
NO950297L (no) Prolinamidderivater
MA26926A1 (fr) Procede d'obtention de formulations aqueuses de principes actifs sensibles a l'oxydation.
JO2239B1 (en) Method for preparing benzothophen derivatives
HU9603185D0 (en) New azolidinediones as antihyperglycemic agents
MY125099A (en) Comminuted form of (s)-2-ethoxy-3-4-(2-4-methanesulfonyloxyphenyl ethoxy) penyl] propanoic acid
MY135954A (en) Crystalline form of (s)-ethoxy-3-4-(2-4-methanesulfonyloxyphenyl ethoxy) phenyl] propanoic acid
EG24223A (en) Stabilized formulations of 6-hydroxy-3-(4-[2-(piperidin-1-yl)ethoxy]phenoxy)-2-(4-methoxyphenyl)benzo[b] thiopehene and salts thereof
BR9812982A (pt) Agente anti-reumático
DE60127535D1 (de) Vorbeugende oder therapeutische mittel gegen gastrische oder ösophageale regurgitation
FI933719A (fi) 4-((2-bensotiazolyl)metylamino)-a-((3,4-difluorfenoxi)metyl)-1-piperidinetanol
EP1757291A3 (en) Stabilized formulations of 6-hydroxy-3-(4-[2-(piperidin-1-YL)ethoxy]phenoxy)-2-(4-methoxyphenyl)benzo[b]thiophene and salts thereof
DK1174131T3 (da) Anvendelse af et middel til forbedring af astrocytfunktion til behandling af Parkinsons sygdom
SE9904412D0 (sv) Comminuted form
HUP0100999A2 (hu) Citosztatikus szerek
DK0673913T3 (da) Calcium-alkalimetalcitratforbindelser samt deres anvendelse som lægemidler
HUP0203476A2 (en) Sodium 2-(4,6-dimethyl-pyrimidin-2-yloxy)-3-(2-(3,4-dimethoxyphenyl)ethoxy)-3,3-diphenylpropionate, use thereof and pharmaceutical composition containing the same
WO2002022567A8 (en) Novel thio derivatives of sordarin as antifungal agents
TW200503680A (en) S-[2-[(1-iminoethyl)amino]ethyl]-2-methyl-l-cysteine maleate form ii crystalline salt
DK0925785T3 (da) Stabiliseret farmaceutisk præparat indeholdende dopamin eller dobutamin
TH61673A (th) สูตรผสมที่เพิ่มความคงตัวของ 6-ไฮดรอกซี-3-(4-[2-(พิเพอริดิน-1-อิล)เอทอกซี]ฟีนอกซี)-2-(4-เมทอกซีเฟนิล)เบนโซ[b]ไทโอฟีนและเกลือของสารดังกล่าว
ES2150392B1 (es) "composiciones parenterales a base de calcitonina".